Alliancebernstein L.P. Altimmune, Inc. Transaction History
Alliancebernstein L.P.
- $300 Billion
- Q3 2025
A detailed history of Alliancebernstein L.P. transactions in Altimmune, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 71,760 shares of ALT stock, worth $291,345. This represents 0.0% of its overall portfolio holdings.
Number of Shares
71,760
Previous 71,760
-0.0%
Holding current value
$291,345
Previous $277,000
2.53%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ALT
# of Institutions
202Shares Held
35.7MCall Options Held
4.88MPut Options Held
4.24M-
Vanguard Group Inc Valley Forge, PA6.37MShares$25.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.32MShares$21.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.6MShares$14.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$11.2 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$8.19 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $199M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...